They are currently under investigation, how do you explain the margins that are obviously much higher than those of the entire industry?
••
@Derspekulant1 Bonus programs, synergy effects, scaling, benefit managers, kick-backs, broader positioning, etc.
You are the top dog, have good agreements and conditions.
It is also normal for others to try to pick up business on the basis of margins. The medication business is quite high-margin. (Of course there will now probably be headwinds and pressure on margins)
As in any other industry, there are attempts to make profits, in most industries there are kick backs, there is always a certain gray area.
With such a huge apparatus and employer, something like this would have come to light much earlier if there was serious evidence, all accusations and investigations have come to nothing, old news is being reheated. It is normal that not everyone is satisfied with such a volume and that there are dissatisfied employees (with 400,000 employees) and customers.
Maybe they should pay a fine and then it's off the table, at least that's my assessment.
I don't think the healthcare system will be overturned, apart from that their Medicaid revenue share is ~ 15%, what do you think will happen with <security:n/a:US60855R1005> - 85% and $CNC ~ 50% and where the customers will then go.
Health dependency/health status and premium portfolio/security, I would probably go to the top dog $UNH. (That's my theory)
At many large companies, some employees get a $UNH contract through cooperations or long-standing $UNH, I don't think this will change so quickly in uncertain times.
There are also health issues, so it's not like you can just change jobs on a whim.
At least that's my opinion, we'll see what happens.
If investing in this area, then rather in the company that has a low Medicaid/Medicare share and is even more attractive after the fall in the share price.
Good risk/reward ratio for me
I may be wrong (on some points), but I like the share price here and you can't compare a private healthcare system, which is more profitable, with a system in Germany or Austria. ✌️
You are the top dog, have good agreements and conditions.
It is also normal for others to try to pick up business on the basis of margins. The medication business is quite high-margin. (Of course there will now probably be headwinds and pressure on margins)
As in any other industry, there are attempts to make profits, in most industries there are kick backs, there is always a certain gray area.
With such a huge apparatus and employer, something like this would have come to light much earlier if there was serious evidence, all accusations and investigations have come to nothing, old news is being reheated. It is normal that not everyone is satisfied with such a volume and that there are dissatisfied employees (with 400,000 employees) and customers.
Maybe they should pay a fine and then it's off the table, at least that's my assessment.
I don't think the healthcare system will be overturned, apart from that their Medicaid revenue share is ~ 15%, what do you think will happen with <security:n/a:US60855R1005> - 85% and $CNC ~ 50% and where the customers will then go.
Health dependency/health status and premium portfolio/security, I would probably go to the top dog $UNH. (That's my theory)
At many large companies, some employees get a $UNH contract through cooperations or long-standing $UNH, I don't think this will change so quickly in uncertain times.
There are also health issues, so it's not like you can just change jobs on a whim.
At least that's my opinion, we'll see what happens.
If investing in this area, then rather in the company that has a low Medicaid/Medicare share and is even more attractive after the fall in the share price.
Good risk/reward ratio for me
I may be wrong (on some points), but I like the share price here and you can't compare a private healthcare system, which is more profitable, with a system in Germany or Austria. ✌️
••
@BamBamInvest So far, however, no one can explain the high margins, no one who has access to the figures and no analyst either. Which is why this is the subject of the investigation. Would be nothing for me 😅
•
22
•@Derspekulant1 This brings opportunities as well as risks 😁 and seriously, the question of margins is only arising now? What about the last 5-10 years, did nobody care? The competition shouldn't have minded either, so if there was something to be found here or something to be found, it would probably be with any of the providers. Excess returns are achieved through false understanding and fear, the psychology of the stock market. Moral sermons would then probably have to be applied in many areas. It remains exciting. I would probably have to accept a crash in the event of potentially poor $ELV figures and prospects today. But here, too, it is important to remember that you have to look at the details and the revenue shares. $UNH has a broader diversification with Optum and Optum Rx. We will see .
••
@BamBamInvest Sure, it's funny that no one noticed before, but the whole thing came about through a whistleblower where the high margins come from, until then it had probably been celebrated rather than perhaps taking a closer look 😅 I mean they are cheap, the only question is whether they will become expensive again.
••